The study is focused on whether doxycycline may slow the progression of emphysema (a type of chronic obstructive pulmonary disease), in people with well-controlled HIV who are current or former smokers.
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the U.S.
IPF, which causes progressive scarring of the lungs due to chronic lung inflammation, is usually fatal because it tends to be diagnosed late in the process when treatments are less effective.
This award is presented annually to members of the Weill Department of Medicine below the rank of professor who perform on outstanding levels in the areas of clinical and/or basic biomedical research.
One of the most prestigious awards in pulmonary and critical care research training, the funding includes $225,000 over three years in support of Dr. Price's research on acute respiratory distress syndrome.
This award was initiated by Dr. Ralph Nachman in 2002 to recognize outstanding research during fellowship training.
Lectures were provided by WDOM faculty and keynote speaker, Dr. Drew Weissman, who played a major role in critical discoveries that allowed for the mRNA platform to be used in developing vaccines against SARS-CoV.
The researchers found that SARS-CoV-2 triggers an inflammatory antiviral response in the adipose tissue (body fat) and causes its dysfunction.
With more than 200 pulmonary disorders that fall under the umbrella of ILD, patient evaluation, proper diagnosis, and determining the best treatment is of the utmost importance.
The Fund for the Future award supports selected junior faculty during the crucial period of career development spanning completion of research training through the early years of their first faculty position at WCM.
